An Open-label, Fixed Sequence Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Repeated Dose of Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers

Trial Profile

An Open-label, Fixed Sequence Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Repeated Dose of Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs Bupropion (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Jul 2016 Status changed from not yet recruiting to completed.
    • 18 Mar 2016 Planned initiation date changed from 1 Mar 2016 to 1 May 2016 as per ClinicalTrials.gov record.
    • 18 Mar 2016 Planned End Date changed from 1 May 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top